ViewpointMT is a world-class organization formed through the merger of Isoray and Viewpoint, with a shared vision of providing personalized and targeted therapies for cancer patients. With over 25 years of experience in the medical technologies market, ViewpointMT is dedicated to advancing cancer treatments using radiation, radiopharmaceuticals, and imaging technologies. Their focus lies in delivering medical doses directly to tumor sites, while sparing healthy tissues, by leveraging innovative approaches like brachytherapy and theranostics.

ViewpointMT's proprietary technologies, such as Cesium-131 brachytherapy radioisotope seeds, offer high energy and a short half-life, enabling aggressive tumor-killing while allowing patients to resume their normal lives. The company's theranostic approach combines diagnostics and therapeutics, using specialized targeting peptides and alpha-particle radiotherapies, to hone in on cancer cells and optimize treatment outcomes. Driven by a commitment to patient-centric innovation, ViewpointMT collaborates with renowned medical institutions and pharmaceutical companies to stay at the forefront of progress and bring about breakthrough solutions.

As leaders in the field, they are actively exploring combination therapies and conducting clinical trials for challenging cancers. Experience the power of ViewpointMT's versatile technologies and join them in their mission to transform cancer care